Biotage AB (LTS:0GRP) LT-Debt-to-Total-Asset : 0.04 (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Biotage AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biotage AB's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.04.

Biotage AB's long-term debt to total assets ratio declined from Dec. 2023 (0.05) to Dec. 2024 (0.04). It may suggest that Biotage AB is progressively becoming less dependent on debt to grow their business.

Biotage AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Biotage AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB LT-Debt-to-Total-Asset Chart

Biotage AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.10

0.09

0.08

0.05

0.04

Biotage AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.07	0.05	0.05	0.04

Biotage AB LT-Debt-to-Total-Asset Calculation

Biotage AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	216	/	5104
	=	0.04

Biotage AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	216	/	5104
	=	0.04

Biotage AB (LTS:0GRP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Biotage AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Biotage AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotage AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (LTS:0GRP) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BITGF:USA BIOT:Sweden BIOTs:UK PQX1:Germany

Address

Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03

Website

https://www.biotage.com

Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB Headlines

No Headlines